Healthcare providers often struggle with complex reimbursement structures, making it difficult to optimize cash flow while ensuring high-quality value-based patient care. Adageis is a forward-thinking healthcare technology company reshaping patient care through flexible AI-centric software solutions for healthcare organizations. The company is able to simplify this process with its AI-powered ProActive Care Platform, a fintech solution designed to make it easy for providers to access the highest-value services available.
One of the core principles guiding Adageis’ approach is simplicity. The platform identifies where providers should be earning more from insurers and guides them on how to secure those payments. The goal is to remove the administrative burden while allowing providers to focus on delivering the best patient care.
A key differentiator for Adageis is its commitment to advocating on behalf of healthcare providers. Instead of leaving providers to navigate complex insurance agreements on their own, the platform offers valuable insights on what they should get from insurance companies for providing high-quality care, ensuring they receive the full reimbursement they are entitled to.
By using predictive analytics through its Patented Risk Engine (“PRE”), Adageis forecasts quality incentive payments and helps providers factor accounts receivables. This proactive approach ensures a steady cash flow, reducing financial uncertainty for healthcare organizations.
One of the biggest hurdles for providers adopting new financial tools is the need for system integration. Adageis simplifies this too, by ensuring its platform works with over 90 EHR systems, including AthenaHealth, Cerner, eClinicalWorks, Allscripts, and Epic. This plug-and-play functionality makes it easier for providers to transition to value-based care without overhauling their existing IT infrastructure.
While Adageis is already being used by 70 providers across two states, the company is working with investors to develop new financial solutions specifically for small and independent healthcare practices. Smaller providers often lack the resources to navigate complex insurance structures, making it harder for them to access high-value services. By expanding its offerings, Adageis aims to bring financial stability and revenue optimization to a broader range of healthcare organizations.
As the healthcare sector continues its shift toward value-based care, Adageis represents a key player in simplifying financial operations for providers, ensuring they can focus on what matters most.
For more information, visit the company’s website at www.Adageis.com.
NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
A team of researchers has developed a “cost-effective” and simple blood test with the potential…
Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible…
Strategic partnerships embrace opportunities to foster innovation, streamline processes and ultimately improve the lives of…
Adageis provides clinics and medical groups with AI-powered tools to track financial outcomes tied to…
Approximately 65% of patients diagnosed with melanoma are unresponsive to immunotherapy. New research suggests that…
Shares of health insurance firms in the U.S. jumped after the federal government announced a…